Company: LGN
Filing Date: 2025-11-03
Form Type: DRS
Source: 0001193125-25-262782
Chunk: 326

Company: Legence Corp.
Filing Date: 2025-11-03
Form: DRS
Chunk 326
---
-----------------|:----|:-----------|--------------:|:----|:---------------|----------:|:----|:-----------|------------------:|:----|:---------------|----------:|
|                  |     | Fair Value |               |     | Carrying Value |           |     | Fair Value |                   |     | Carrying Value |           |
| Term loan        |     | $          |     1,585,138 |     | $              | 1,569,948 |     | $          |         1,597,825 |     | $              | 1,576,502 |
| Promissory notes |     | $          |        19,285 |     | $              |    21,608 |     | $          |            19,475 |     | $              |    22,646 |

F-75

Confidential Treatment Requested by Legence Corp. Pursuant to 17 C.F.R. Section 200.83 The fair value of the term loan as of June 30, 2025 and December 31, 2024 was derived by taking the mid-pointof the trading prices from observable market inputs in the secondary bond market for the term loan (Level 2 measurement) and multiplying it by the outstanding face value of the term loan. The fair value of the promissory notes as of June 30, 2025 and December 31, 2024 was calculated using a discounted cash flow methodology under the income approach, using interest rate indices, risk premiums, and adjustments for the size and subordination of the instrument (Level 3 measurement). The carrying value of the remaining notes payable and finance lease liabilities approximates fair value as of June 30, 2025 and December 31, 2024. Note 9—Derivatives I nterest Rate Swaps:The Company has multiple interest rate swap agreements designated as cash flow hedges. The Company utilizes these interest rate swap agreements to reduce exposure to fluctuations in variable interest rates for future interest payments on its term loan. The total notional amount is $815.0 million as of both June 30, 2025 and December 31, 2024. Failure of the interest rate swap counterparties to make payments may result in the loss of any potential benefit to the Company under the interest rate swap agreements. The Company mitigates risk of non-performanceby counterparties by dealing with highly rated counterparties. The Company does not use financial instruments